Showing 5491-5500 of 8791 results for "".
- gel-e Receives US FDA Clearance to Expand its Bandage Product Line for Rx, OTC Usehttps://practicaldermatology.com/news/gel-e-receives-us-fda-clearance-to-expand-its-bandage-product-line-for-rx-otc-use/2457951/The U.S. Food and Drug Administration (FDA) has cleared gel-e Inc.’s adhesive bandage for prescription (Rx) and over-the-counter (OTC) use. This 510(k) clearance expands the Company's label to include the ma
- Harnessing the Power of Social Media: One Viral Post Can Generate Tons of Skin Cancer Awarenesshttps://practicaldermatology.com/news/harnessing-the-power-of-social-media-one-viral-post-can-generate-tons-of-skin-cancer-awareness/2457953/You don’t have to be a celebrity to give voice to a public health concern on social media. Just one person can generate awareness about skin cancer -- when his or her post and picture is shared thousands of times on Facebook, researchers report in the journal Preventive Medicine
- Study: Minorities Less Likely to See a Doctor for Psoriasishttps://practicaldermatology.com/news/study-minorities-less-likely-to-see-a-doctor-for-psoriasis/2457954/Minorities are less likely than white Americans to see a doctor for psoriasis treatment despite the fact that their disease may be more severe, a new study shows. Researchers from the Perelman School of Medicine at the University of Pennsylvania fou
- Almirall and Athenex Form Strategic Partnership for Treatment of AKshttps://practicaldermatology.com/news/almirall-and-athenex-form-strategic-partnership-for-treatment-of-aks/2457957/Almirall, S.A and Athenex, Inc. recently formed a partnership to further develop and commercialize KX2-391 for the treatment of actinic keratosis (AK) and other skin conditions. Subject to the terms and conditions of the license agreement, Athenex will grant to Almirall an exclusive
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjectorhttps://practicaldermatology.com/news/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector/2457966/Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional administration option for appropriate Enbrel patients. T
- Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoseshttps://practicaldermatology.com/news/parent-supplied-photos-may-allow-pediatric-derms-to-make-virtual-diagnoses/2457968/Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear in JAMA Dermatology, suggest that direct-to-patient dermatology can accurate
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea